Innovent Biologics (STU:6IB) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Innovent Biologics's Capital Expenditure for the six months ended in Dec. 2023 was €-97.23 Mil. Its Operating Income for the six months ended in Dec. 2023 was €-60.04 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Innovent Biologics Capex-to-Operating-Income Historical Data

The historical data trend for Innovent Biologics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Capex-to-Operating-Income Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Get a 7-Day Free Trial

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Operating-Income	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Innovent Biologics's Capex-to-Operating-Income

For the Biotechnology subindustry, Innovent Biologics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Capex-to-Operating-Income falls into.

Innovent Biologics Capex-to-Operating-Income Calculation

Innovent Biologics's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-177.675)	/	-116.768
	=	N/A

Innovent Biologics's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-97.227)	/	-60.041
	=	N/A

Innovent Biologics (STU:6IB) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Innovent Biologics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics (STU:6IB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (STU:6IB) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 01801:Hong Kong

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (STU:6IB) Headlines

No Headlines